SAMHSA extends methadone take-home flexibilities initiated during pandemic
 
The Substance Abuse and Mental Health Services Administration yesterday extended certain methadone take-home flexibilities for opioid treatment programs until one year after the end of the COVID-19 public health emergency, and said it is considering ways to make the flexibilities permanent.
SAMHSA in 2020 allowed states to request a blanket exception to allow stable patients in an opioid treatment program to receive 28 days of take-home doses of their OUD medication, and other eligible patients to receive up to 14 days of take-home medication, which the agency said has enhanced and encouraged use of treatment services.
 
Related News Articles
Perspective
  More than 48 million Americans — 16.8% of the 12-and-older population — have a substance use disorder (SUD), according to the 2025 National Survey on Drug Use…
  Headline
  HHS awards $1.5 billion in opioid response grants to states, tribal communities The Department of Health and Human Services announced yesterday that it…
  Headline
  The Senate Sept. 18 passed the AHA-supported SUPPORT Act (H.R. 2483) by a voice vote, advancing the bill to President Trump to sign into law. The bill…
  Headline
  The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
  Headline
  A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
  Headline
  The Centers for Disease Control and Prevention Aug. 5 announced a new campaign educating youth ages 12-17 on substance use, mental health and how they are…
  